Atgam Efficacy and Safety in Moderate-to-Very Severe Acquired Aplastic Anemia: Outcome of a Large Multicenter Cohort of 634 Children and Adults from the French Authorization for Temporary Use Surveillance Program

Introduction Acquired aplastic anemia (AA) is a rare immunological disease leading to bone marrow failure. First-line treatment in patients aged >40 years or without a matched related donor is immunosuppressive therapy (IST) based on anti-human T lymphocyte immunoglobulin (ATG) plus cyclosporine....

Full description

Saved in:
Bibliographic Details
Published in:Blood 2023-11, Vol.142 (Supplement 1), p.1347-1347
Main Authors: Sicre De Fontbrune, Flore, Fahd, Mony, Forcade, Édouard, Tavitian, Suzanne, Moluçon Chabrot, Cécile, Barraco, Fiorenza, Hicheri, Yosr, Lebon, Delphine, Maury, Sébastien, Menard, Anne-Lise, Możejko-Pastewka, Barbara, Wolter, Kevin D, Valtier, Bruno, Leblanc, Thierry, Peffault De Latour, Regis
Format: Article
Language:English
Subjects:
Human health and pathology
Life Sciences
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 1347
container_issue Supplement 1
container_start_page 1347
container_title Blood
container_volume 142
creator Sicre De Fontbrune, Flore
Fahd, Mony
Forcade, Édouard
Tavitian, Suzanne
Moluçon Chabrot, Cécile
Barraco, Fiorenza
Hicheri, Yosr
Lebon, Delphine
Maury, Sébastien
Menard, Anne-Lise
Możejko-Pastewka, Barbara
Wolter, Kevin D
Valtier, Bruno
Leblanc, Thierry
Peffault De Latour, Regis
description Introduction Acquired aplastic anemia (AA) is a rare immunological disease leading to bone marrow failure. First-line treatment in patients aged >40 years or without a matched related donor is immunosuppressive therapy (IST) based on anti-human T lymphocyte immunoglobulin (ATG) plus cyclosporine. This ATGAM Temporary Use Authorization program was a retrospective, multicenter study to report safety and efficacy surveillance data on ATGAM use in patients with AA. Methods This study collected surveillance data from the ATGAM Named Patients Program for French authorities ahead of ATGAM registration. Patients were treated with ATGAM 40 mg/kg for 4 days in addition to cyclosporine. Safety and efficacy data were collected from patients treated from September 2011 to August 2022 and reported to the French authority every 6 months. Patients were classified as severe AA if they had 2 of the following criteria: neutrophil count 2.0x10 9/L and platelet count >100x10 9/L; partial response: neutrophil count >1.0x10 9/L and platelet count >30x10 9/L; no response: transfusion dependent. Patients were classified as receiving first-line treatment (never received ATG), refractory (failed to respond to previous IST with ATG within 12 months before initial ATGAM), or relapse (recurrence of AA after a positive response to IST with ATG), regardless of AA severity. Results In total, 634 patients with moderate-to-very severe AA were treated with ATGAM (n=537 first-line; n=68 refractory/relapse; n=29 not classified) in addition to cyclosporine (40 first-line patients also received eltrombopag) from January 2012 to August 2022. By severity, n=124 were moderate, n=317 severe, n=133 very severe, and n=60 severity unknown. Patient demographics are shown in Table 1. Overall response (partial+complete) in patients on first-line th
doi_str_mv 10.1182/blood-2023-186493
format article
fullrecord <record><control><sourceid>hal_cross</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_04326265v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0006497123079508</els_id><sourcerecordid>oai_HAL_hal_04326265v1</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1281-f90d9f0a6d96db5dc3083ad94c0a737aa938cbc68b56e9a47a29d9b419220ef83</originalsourceid><addsrcrecordid>eNp9kU2P0zAQhiMEEmXhB3CbK4eA7Xw0hlNU7QdSV4vUXa7WxB43RklcHKdS-Z38INwt4sjJ0sz7jGfeN8vec_aR80Z86gbvTS6YKHLe1KUsXmQrXokmZ0ywl9mKMVbnpVzz19mbef7BGC8LUa2y323c4wjX1jqN-gQ4GdihpXgCN8G9NxQwUh59_p3CCXZ0pEDQ6p-LC2SgPQw4R6ehnWh0-Bkelqj9SOAtIGwx7AnulyEpaIoUYON7H-K5WxclbHo3mEDT86-tSboZbPAjxJ7gJjV0D-0SE-J-YXR-AusDPNJ48AHTNk8zwW4JR3LDgJMm-Bb8PuD4NntlcZjp3d_3Knu6uX7c3OXbh9uvm3abay4anlvJjLQMayNr01VGF6wp0MhSM1wXa0RZNLrTddNVNUks1yikkV3JpRCMbFNcZR8uc3sc1CG4MS2lPDp1127VucaSybWoqyNPWn7R6uDnOZD9B3CmzhGq5wjVOUJ1iTAxXy4MpSOOjoKatUuukEnm66iMd_-h_wAtNab3</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Atgam Efficacy and Safety in Moderate-to-Very Severe Acquired Aplastic Anemia: Outcome of a Large Multicenter Cohort of 634 Children and Adults from the French Authorization for Temporary Use Surveillance Program</title><source>ScienceDirect®</source><creator>Sicre De Fontbrune, Flore ; Fahd, Mony ; Forcade, Édouard ; Tavitian, Suzanne ; Moluçon Chabrot, Cécile ; Barraco, Fiorenza ; Hicheri, Yosr ; Lebon, Delphine ; Maury, Sébastien ; Menard, Anne-Lise ; Możejko-Pastewka, Barbara ; Wolter, Kevin D ; Valtier, Bruno ; Leblanc, Thierry ; Peffault De Latour, Regis</creator><creatorcontrib>Sicre De Fontbrune, Flore ; Fahd, Mony ; Forcade, Édouard ; Tavitian, Suzanne ; Moluçon Chabrot, Cécile ; Barraco, Fiorenza ; Hicheri, Yosr ; Lebon, Delphine ; Maury, Sébastien ; Menard, Anne-Lise ; Możejko-Pastewka, Barbara ; Wolter, Kevin D ; Valtier, Bruno ; Leblanc, Thierry ; Peffault De Latour, Regis</creatorcontrib><description>Introduction Acquired aplastic anemia (AA) is a rare immunological disease leading to bone marrow failure. First-line treatment in patients aged &gt;40 years or without a matched related donor is immunosuppressive therapy (IST) based on anti-human T lymphocyte immunoglobulin (ATG) plus cyclosporine. This ATGAM Temporary Use Authorization program was a retrospective, multicenter study to report safety and efficacy surveillance data on ATGAM use in patients with AA. Methods This study collected surveillance data from the ATGAM Named Patients Program for French authorities ahead of ATGAM registration. Patients were treated with ATGAM 40 mg/kg for 4 days in addition to cyclosporine. Safety and efficacy data were collected from patients treated from September 2011 to August 2022 and reported to the French authority every 6 months. Patients were classified as severe AA if they had 2 of the following criteria: neutrophil count &lt;0.5x10 9/L, platelet count &lt;20x10 9/L, or reticulocyte count &lt;60x10 9/L. Very severe AA: same as severe except neutrophil count &lt;0.2x10 9/L. Patients not meeting criteria for very severe/severe AA were classified as moderate. Patient response was evaluated using the RACE study criteria (Peffault de Latour, et al [2022]), for severe AA: complete response was defined as: hemoglobin &gt;100g/L, neutrophil count &gt;1.0x10 9/L, and platelet count &gt;100x10 9/L; partial response: no longer meeting criteria for severe disease; no response: still severe AA and/or transfusion dependent. For moderate AA (Marsh, et al [1999]), complete response was defined as: neutrophil count &gt;2.0x10 9/L and platelet count &gt;100x10 9/L; partial response: neutrophil count &gt;1.0x10 9/L and platelet count &gt;30x10 9/L; no response: transfusion dependent. Patients were classified as receiving first-line treatment (never received ATG), refractory (failed to respond to previous IST with ATG within 12 months before initial ATGAM), or relapse (recurrence of AA after a positive response to IST with ATG), regardless of AA severity. Results In total, 634 patients with moderate-to-very severe AA were treated with ATGAM (n=537 first-line; n=68 refractory/relapse; n=29 not classified) in addition to cyclosporine (40 first-line patients also received eltrombopag) from January 2012 to August 2022. By severity, n=124 were moderate, n=317 severe, n=133 very severe, and n=60 severity unknown. Patient demographics are shown in Table 1. Overall response (partial+complete) in patients on first-line therapy at 3, 6, and 12 months was 22.5% (n=78), 50.6% (n=156), and 79.2% (n=164), respectively. By severity, overall response rates in first-line therapy for moderate and severe/very severe cohorts, respectively, were: 25.0% (n=20) and 21.7% (n=58) at 3 months; 56.8% (n=42) and 48.7% (n=114) at 6 months; and 74.1% (n=40) and 81.0% (n=124) at 12 months. Overall response at 6 and 12 months by age and AA severity in patients on first-line treatment is shown in Table 2. Median duration of follow-up was 12.4 months. Overall survival (95% confidence interval) at 12 months for all patients was 91.5% (88.8-93.6). The treatment was well tolerated, and no new safety signals were observed with ATGAM. Cumulatively, 1,087 adverse events were reported in 364 patients over the entire program period, the majority of which were disease related. Conclusion This real-world, retrospective study utilizing surveillance data showed response rates in line with the recent RACE study (Peffault de Latour, et al [2022]) for patients with first-line severe AA treated with a combination of ATGAM and cyclosporine. No new safety risks were identified in this large cohort of patients. Treatment with ATGAM remains of benefit in patients with moderate-to-very severe AA. Sicre De Fontbrune:Alexion, AstraZeneca Rare Disease: Honoraria, Research Funding; Sobi: Honoraria, Research Funding; Samsung: Honoraria, Research Funding; Novartis: Honoraria, Research Funding. Forcade:Jazz: Other: Travel support; Novartis: Consultancy, Other: Travel support, Speakers Bureau; Alexion: Other: Travel support, Speakers Bureau; Astellas: Speakers Bureau; Gilead Sciences: Other: Travel support, Speakers Bureau; GSK: Speakers Bureau; Sanofi: Speakers Bureau; MSD: Other: Travel support. Możejko-Pastewka:Pfizer: Current Employment, Current equity holder in publicly-traded company. Wolter:Pfizer: Current Employment, Current equity holder in publicly-traded company. Valtier:Pfizer: Current Employment, Current equity holder in publicly-traded company. Leblanc:Alexion: Other: Travel support. Peffault De Latour:Jazz Pharmaceuticals: Honoraria. [Display omitted]</description><identifier>ISSN: 0006-4971</identifier><identifier>EISSN: 1528-0020</identifier><identifier>DOI: 10.1182/blood-2023-186493</identifier><language>eng</language><publisher>Elsevier Inc</publisher><subject>Human health and pathology ; Life Sciences</subject><ispartof>Blood, 2023-11, Vol.142 (Supplement 1), p.1347-1347</ispartof><rights>2023 The American Society of Hematology</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><orcidid>0000-0002-4073-1559</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0006497123079508$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3536,27901,27902,45756</link.rule.ids><backlink>$$Uhttps://u-picardie.hal.science/hal-04326265$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Sicre De Fontbrune, Flore</creatorcontrib><creatorcontrib>Fahd, Mony</creatorcontrib><creatorcontrib>Forcade, Édouard</creatorcontrib><creatorcontrib>Tavitian, Suzanne</creatorcontrib><creatorcontrib>Moluçon Chabrot, Cécile</creatorcontrib><creatorcontrib>Barraco, Fiorenza</creatorcontrib><creatorcontrib>Hicheri, Yosr</creatorcontrib><creatorcontrib>Lebon, Delphine</creatorcontrib><creatorcontrib>Maury, Sébastien</creatorcontrib><creatorcontrib>Menard, Anne-Lise</creatorcontrib><creatorcontrib>Możejko-Pastewka, Barbara</creatorcontrib><creatorcontrib>Wolter, Kevin D</creatorcontrib><creatorcontrib>Valtier, Bruno</creatorcontrib><creatorcontrib>Leblanc, Thierry</creatorcontrib><creatorcontrib>Peffault De Latour, Regis</creatorcontrib><title>Atgam Efficacy and Safety in Moderate-to-Very Severe Acquired Aplastic Anemia: Outcome of a Large Multicenter Cohort of 634 Children and Adults from the French Authorization for Temporary Use Surveillance Program</title><title>Blood</title><description>Introduction Acquired aplastic anemia (AA) is a rare immunological disease leading to bone marrow failure. First-line treatment in patients aged &gt;40 years or without a matched related donor is immunosuppressive therapy (IST) based on anti-human T lymphocyte immunoglobulin (ATG) plus cyclosporine. This ATGAM Temporary Use Authorization program was a retrospective, multicenter study to report safety and efficacy surveillance data on ATGAM use in patients with AA. Methods This study collected surveillance data from the ATGAM Named Patients Program for French authorities ahead of ATGAM registration. Patients were treated with ATGAM 40 mg/kg for 4 days in addition to cyclosporine. Safety and efficacy data were collected from patients treated from September 2011 to August 2022 and reported to the French authority every 6 months. Patients were classified as severe AA if they had 2 of the following criteria: neutrophil count &lt;0.5x10 9/L, platelet count &lt;20x10 9/L, or reticulocyte count &lt;60x10 9/L. Very severe AA: same as severe except neutrophil count &lt;0.2x10 9/L. Patients not meeting criteria for very severe/severe AA were classified as moderate. Patient response was evaluated using the RACE study criteria (Peffault de Latour, et al [2022]), for severe AA: complete response was defined as: hemoglobin &gt;100g/L, neutrophil count &gt;1.0x10 9/L, and platelet count &gt;100x10 9/L; partial response: no longer meeting criteria for severe disease; no response: still severe AA and/or transfusion dependent. For moderate AA (Marsh, et al [1999]), complete response was defined as: neutrophil count &gt;2.0x10 9/L and platelet count &gt;100x10 9/L; partial response: neutrophil count &gt;1.0x10 9/L and platelet count &gt;30x10 9/L; no response: transfusion dependent. Patients were classified as receiving first-line treatment (never received ATG), refractory (failed to respond to previous IST with ATG within 12 months before initial ATGAM), or relapse (recurrence of AA after a positive response to IST with ATG), regardless of AA severity. Results In total, 634 patients with moderate-to-very severe AA were treated with ATGAM (n=537 first-line; n=68 refractory/relapse; n=29 not classified) in addition to cyclosporine (40 first-line patients also received eltrombopag) from January 2012 to August 2022. By severity, n=124 were moderate, n=317 severe, n=133 very severe, and n=60 severity unknown. Patient demographics are shown in Table 1. Overall response (partial+complete) in patients on first-line therapy at 3, 6, and 12 months was 22.5% (n=78), 50.6% (n=156), and 79.2% (n=164), respectively. By severity, overall response rates in first-line therapy for moderate and severe/very severe cohorts, respectively, were: 25.0% (n=20) and 21.7% (n=58) at 3 months; 56.8% (n=42) and 48.7% (n=114) at 6 months; and 74.1% (n=40) and 81.0% (n=124) at 12 months. Overall response at 6 and 12 months by age and AA severity in patients on first-line treatment is shown in Table 2. Median duration of follow-up was 12.4 months. Overall survival (95% confidence interval) at 12 months for all patients was 91.5% (88.8-93.6). The treatment was well tolerated, and no new safety signals were observed with ATGAM. Cumulatively, 1,087 adverse events were reported in 364 patients over the entire program period, the majority of which were disease related. Conclusion This real-world, retrospective study utilizing surveillance data showed response rates in line with the recent RACE study (Peffault de Latour, et al [2022]) for patients with first-line severe AA treated with a combination of ATGAM and cyclosporine. No new safety risks were identified in this large cohort of patients. Treatment with ATGAM remains of benefit in patients with moderate-to-very severe AA. Sicre De Fontbrune:Alexion, AstraZeneca Rare Disease: Honoraria, Research Funding; Sobi: Honoraria, Research Funding; Samsung: Honoraria, Research Funding; Novartis: Honoraria, Research Funding. Forcade:Jazz: Other: Travel support; Novartis: Consultancy, Other: Travel support, Speakers Bureau; Alexion: Other: Travel support, Speakers Bureau; Astellas: Speakers Bureau; Gilead Sciences: Other: Travel support, Speakers Bureau; GSK: Speakers Bureau; Sanofi: Speakers Bureau; MSD: Other: Travel support. Możejko-Pastewka:Pfizer: Current Employment, Current equity holder in publicly-traded company. Wolter:Pfizer: Current Employment, Current equity holder in publicly-traded company. Valtier:Pfizer: Current Employment, Current equity holder in publicly-traded company. Leblanc:Alexion: Other: Travel support. Peffault De Latour:Jazz Pharmaceuticals: Honoraria. [Display omitted]</description><subject>Human health and pathology</subject><subject>Life Sciences</subject><issn>0006-4971</issn><issn>1528-0020</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNp9kU2P0zAQhiMEEmXhB3CbK4eA7Xw0hlNU7QdSV4vUXa7WxB43RklcHKdS-Z38INwt4sjJ0sz7jGfeN8vec_aR80Z86gbvTS6YKHLe1KUsXmQrXokmZ0ywl9mKMVbnpVzz19mbef7BGC8LUa2y323c4wjX1jqN-gQ4GdihpXgCN8G9NxQwUh59_p3CCXZ0pEDQ6p-LC2SgPQw4R6ehnWh0-Bkelqj9SOAtIGwx7AnulyEpaIoUYON7H-K5WxclbHo3mEDT86-tSboZbPAjxJ7gJjV0D-0SE-J-YXR-AusDPNJ48AHTNk8zwW4JR3LDgJMm-Bb8PuD4NntlcZjp3d_3Knu6uX7c3OXbh9uvm3abay4anlvJjLQMayNr01VGF6wp0MhSM1wXa0RZNLrTddNVNUks1yikkV3JpRCMbFNcZR8uc3sc1CG4MS2lPDp1127VucaSybWoqyNPWn7R6uDnOZD9B3CmzhGq5wjVOUJ1iTAxXy4MpSOOjoKatUuukEnm66iMd_-h_wAtNab3</recordid><startdate>20231102</startdate><enddate>20231102</enddate><creator>Sicre De Fontbrune, Flore</creator><creator>Fahd, Mony</creator><creator>Forcade, Édouard</creator><creator>Tavitian, Suzanne</creator><creator>Moluçon Chabrot, Cécile</creator><creator>Barraco, Fiorenza</creator><creator>Hicheri, Yosr</creator><creator>Lebon, Delphine</creator><creator>Maury, Sébastien</creator><creator>Menard, Anne-Lise</creator><creator>Możejko-Pastewka, Barbara</creator><creator>Wolter, Kevin D</creator><creator>Valtier, Bruno</creator><creator>Leblanc, Thierry</creator><creator>Peffault De Latour, Regis</creator><general>Elsevier Inc</general><general>American Society of Hematology</general><scope>AAYXX</scope><scope>CITATION</scope><scope>1XC</scope><orcidid>https://orcid.org/0000-0002-4073-1559</orcidid></search><sort><creationdate>20231102</creationdate><title>Atgam Efficacy and Safety in Moderate-to-Very Severe Acquired Aplastic Anemia: Outcome of a Large Multicenter Cohort of 634 Children and Adults from the French Authorization for Temporary Use Surveillance Program</title><author>Sicre De Fontbrune, Flore ; Fahd, Mony ; Forcade, Édouard ; Tavitian, Suzanne ; Moluçon Chabrot, Cécile ; Barraco, Fiorenza ; Hicheri, Yosr ; Lebon, Delphine ; Maury, Sébastien ; Menard, Anne-Lise ; Możejko-Pastewka, Barbara ; Wolter, Kevin D ; Valtier, Bruno ; Leblanc, Thierry ; Peffault De Latour, Regis</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1281-f90d9f0a6d96db5dc3083ad94c0a737aa938cbc68b56e9a47a29d9b419220ef83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Human health and pathology</topic><topic>Life Sciences</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sicre De Fontbrune, Flore</creatorcontrib><creatorcontrib>Fahd, Mony</creatorcontrib><creatorcontrib>Forcade, Édouard</creatorcontrib><creatorcontrib>Tavitian, Suzanne</creatorcontrib><creatorcontrib>Moluçon Chabrot, Cécile</creatorcontrib><creatorcontrib>Barraco, Fiorenza</creatorcontrib><creatorcontrib>Hicheri, Yosr</creatorcontrib><creatorcontrib>Lebon, Delphine</creatorcontrib><creatorcontrib>Maury, Sébastien</creatorcontrib><creatorcontrib>Menard, Anne-Lise</creatorcontrib><creatorcontrib>Możejko-Pastewka, Barbara</creatorcontrib><creatorcontrib>Wolter, Kevin D</creatorcontrib><creatorcontrib>Valtier, Bruno</creatorcontrib><creatorcontrib>Leblanc, Thierry</creatorcontrib><creatorcontrib>Peffault De Latour, Regis</creatorcontrib><collection>CrossRef</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>Blood</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sicre De Fontbrune, Flore</au><au>Fahd, Mony</au><au>Forcade, Édouard</au><au>Tavitian, Suzanne</au><au>Moluçon Chabrot, Cécile</au><au>Barraco, Fiorenza</au><au>Hicheri, Yosr</au><au>Lebon, Delphine</au><au>Maury, Sébastien</au><au>Menard, Anne-Lise</au><au>Możejko-Pastewka, Barbara</au><au>Wolter, Kevin D</au><au>Valtier, Bruno</au><au>Leblanc, Thierry</au><au>Peffault De Latour, Regis</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Atgam Efficacy and Safety in Moderate-to-Very Severe Acquired Aplastic Anemia: Outcome of a Large Multicenter Cohort of 634 Children and Adults from the French Authorization for Temporary Use Surveillance Program</atitle><jtitle>Blood</jtitle><date>2023-11-02</date><risdate>2023</risdate><volume>142</volume><issue>Supplement 1</issue><spage>1347</spage><epage>1347</epage><pages>1347-1347</pages><issn>0006-4971</issn><eissn>1528-0020</eissn><abstract>Introduction Acquired aplastic anemia (AA) is a rare immunological disease leading to bone marrow failure. First-line treatment in patients aged &gt;40 years or without a matched related donor is immunosuppressive therapy (IST) based on anti-human T lymphocyte immunoglobulin (ATG) plus cyclosporine. This ATGAM Temporary Use Authorization program was a retrospective, multicenter study to report safety and efficacy surveillance data on ATGAM use in patients with AA. Methods This study collected surveillance data from the ATGAM Named Patients Program for French authorities ahead of ATGAM registration. Patients were treated with ATGAM 40 mg/kg for 4 days in addition to cyclosporine. Safety and efficacy data were collected from patients treated from September 2011 to August 2022 and reported to the French authority every 6 months. Patients were classified as severe AA if they had 2 of the following criteria: neutrophil count &lt;0.5x10 9/L, platelet count &lt;20x10 9/L, or reticulocyte count &lt;60x10 9/L. Very severe AA: same as severe except neutrophil count &lt;0.2x10 9/L. Patients not meeting criteria for very severe/severe AA were classified as moderate. Patient response was evaluated using the RACE study criteria (Peffault de Latour, et al [2022]), for severe AA: complete response was defined as: hemoglobin &gt;100g/L, neutrophil count &gt;1.0x10 9/L, and platelet count &gt;100x10 9/L; partial response: no longer meeting criteria for severe disease; no response: still severe AA and/or transfusion dependent. For moderate AA (Marsh, et al [1999]), complete response was defined as: neutrophil count &gt;2.0x10 9/L and platelet count &gt;100x10 9/L; partial response: neutrophil count &gt;1.0x10 9/L and platelet count &gt;30x10 9/L; no response: transfusion dependent. Patients were classified as receiving first-line treatment (never received ATG), refractory (failed to respond to previous IST with ATG within 12 months before initial ATGAM), or relapse (recurrence of AA after a positive response to IST with ATG), regardless of AA severity. Results In total, 634 patients with moderate-to-very severe AA were treated with ATGAM (n=537 first-line; n=68 refractory/relapse; n=29 not classified) in addition to cyclosporine (40 first-line patients also received eltrombopag) from January 2012 to August 2022. By severity, n=124 were moderate, n=317 severe, n=133 very severe, and n=60 severity unknown. Patient demographics are shown in Table 1. Overall response (partial+complete) in patients on first-line therapy at 3, 6, and 12 months was 22.5% (n=78), 50.6% (n=156), and 79.2% (n=164), respectively. By severity, overall response rates in first-line therapy for moderate and severe/very severe cohorts, respectively, were: 25.0% (n=20) and 21.7% (n=58) at 3 months; 56.8% (n=42) and 48.7% (n=114) at 6 months; and 74.1% (n=40) and 81.0% (n=124) at 12 months. Overall response at 6 and 12 months by age and AA severity in patients on first-line treatment is shown in Table 2. Median duration of follow-up was 12.4 months. Overall survival (95% confidence interval) at 12 months for all patients was 91.5% (88.8-93.6). The treatment was well tolerated, and no new safety signals were observed with ATGAM. Cumulatively, 1,087 adverse events were reported in 364 patients over the entire program period, the majority of which were disease related. Conclusion This real-world, retrospective study utilizing surveillance data showed response rates in line with the recent RACE study (Peffault de Latour, et al [2022]) for patients with first-line severe AA treated with a combination of ATGAM and cyclosporine. No new safety risks were identified in this large cohort of patients. Treatment with ATGAM remains of benefit in patients with moderate-to-very severe AA. Sicre De Fontbrune:Alexion, AstraZeneca Rare Disease: Honoraria, Research Funding; Sobi: Honoraria, Research Funding; Samsung: Honoraria, Research Funding; Novartis: Honoraria, Research Funding. Forcade:Jazz: Other: Travel support; Novartis: Consultancy, Other: Travel support, Speakers Bureau; Alexion: Other: Travel support, Speakers Bureau; Astellas: Speakers Bureau; Gilead Sciences: Other: Travel support, Speakers Bureau; GSK: Speakers Bureau; Sanofi: Speakers Bureau; MSD: Other: Travel support. Możejko-Pastewka:Pfizer: Current Employment, Current equity holder in publicly-traded company. Wolter:Pfizer: Current Employment, Current equity holder in publicly-traded company. Valtier:Pfizer: Current Employment, Current equity holder in publicly-traded company. Leblanc:Alexion: Other: Travel support. Peffault De Latour:Jazz Pharmaceuticals: Honoraria. [Display omitted]</abstract><pub>Elsevier Inc</pub><doi>10.1182/blood-2023-186493</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0002-4073-1559</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0006-4971
ispartof Blood, 2023-11, Vol.142 (Supplement 1), p.1347-1347
issn 0006-4971
1528-0020
language eng
recordid cdi_hal_primary_oai_HAL_hal_04326265v1
source ScienceDirect®
subjects Human health and pathology
Life Sciences
title Atgam Efficacy and Safety in Moderate-to-Very Severe Acquired Aplastic Anemia: Outcome of a Large Multicenter Cohort of 634 Children and Adults from the French Authorization for Temporary Use Surveillance Program
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T12%3A05%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-hal_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Atgam%20Efficacy%20and%20Safety%20in%20Moderate-to-Very%20Severe%20Acquired%20Aplastic%20Anemia:%20Outcome%20of%20a%20Large%20Multicenter%20Cohort%20of%20634%20Children%20and%20Adults%20from%20the%20French%20Authorization%20for%20Temporary%20Use%20Surveillance%20Program&rft.jtitle=Blood&rft.au=Sicre%20De%20Fontbrune,%20Flore&rft.date=2023-11-02&rft.volume=142&rft.issue=Supplement%201&rft.spage=1347&rft.epage=1347&rft.pages=1347-1347&rft.issn=0006-4971&rft.eissn=1528-0020&rft_id=info:doi/10.1182/blood-2023-186493&rft_dat=%3Chal_cross%3Eoai_HAL_hal_04326265v1%3C/hal_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c1281-f90d9f0a6d96db5dc3083ad94c0a737aa938cbc68b56e9a47a29d9b419220ef83%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true